Ad5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases

Molecular Therapy

Volumn 22, Issue 8, 2014, Pages 1504-1517

  Xu, Weidong ^a   Zhang, Zhenwei ^a   Yang, Yuefeng ^a   Hu, Zebin ^a   Wang, Chi Hsiung ^a   Morgan, Melanie ^a   Wu, Ying ^a   Hutten, Ryan ^a   Xiao, Xianghui ^b   Stock, Stuart ^c   Guise, Theresa ^d   Prabhakar, Bellur S ^e   Brendler, Charles ^a   Seth, Prem ^a  

^a NorthShore University Research Institute   (United States)

^b ARGONNE NATIONAL LABORATORY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 6; LACTATE DEHYDROGENASE; ONCOLYTIC VIRUS; SOLUBLE TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2 IMMUNOGLOBULIN FC FRAGMENT FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CAPSID PROTEIN; HEXON CAPSID PROTEIN, ADENOVIRUS; HYBRID PROTEIN; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR-BETA TYPE II RECEPTOR; ONCOLYTIC ADENOVIRUS; SOLUBLE TRANSFORMING GROWTH FACTOR BETA RECEPTOR II FC FUSION PROTEIN; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; CELL SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; HYPERTRANSAMINASEMIA; LIVER DISEASE; LIVER NECROSIS; LIVER TOXICITY; MALE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; VIRAL GENE THERAPY; VIRUS PARTICLE; VIRUS REPLICATION; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; ANIMAL; BONE NEOPLASMS; CANCER TRANSPLANTATION; CLASSIFICATION; DEPENDOPARVOVIRUS; GENE VECTOR; GENETICS; LIVER; METABOLISM; NUDE MOUSE; ONCOLYTIC VIROTHERAPY; PATHOLOGY; PROSTATIC NEOPLASMS; SECONDARY; THERAPEUTIC USE; TUMOR CELL LINE; ADENOVIRUS; ADENOVIRUS 48; BONE DESTRUCTION; DRUG MEGADOSE; HYPERCALCEMIA; INNATE IMMUNITY; LOW DRUG DOSE; OSTEOCLAST ACTIVITY; SPLEEN;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; MUS MUSCULUS;

ANIMALS; BONE NEOPLASMS; CAPSID PROTEINS; CELL LINE, TUMOR; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; LIVER; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECOMBINANT FUSION PROTEINS;

EID: 84905506873     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.80     Document Type: Article

References (49)

1. Coleman, RE (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27: 165-176.
2. Harris, WP, Mostaghel, EA, Nelson, PS and Montgomery, B (2009). Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6: 76-85.
3. Cannata, DH, Kirschenbaum, A and Levine, AC (2012). Androgen deprivation therapy as primary treatment for prostate cancer. J Clin Endocrinol Metab 97: 360-365.
4. Coleman, R (2011). The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci 1218: 3-14.
5. Smith, MR, Saad, F, Coleman, R, Shore, N, Fizazi, K, Tombal, B et al. (2012). Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 379: 39-46.
6. Fizazi, K, Carducci, M, Smith, M, Damião, R, Brown, J, Karsh, L et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377: 813-822.
7. Sturge, J, Caley, MP and Waxman, J (2011). Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 8: 357-368.
8. Bischoff, JR, Kirn, DH, Williams, A, Heise, C, Horn, S, Muna, M et al. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376.
9. Seth, P (ed) (1999). Adenoviruses: Basic Biology to Gene Therapy. R G Landes Company: Austin. pp. 1-314.
10. Toth, K, Dhar, D and Wold, WS (2010). Oncolytic (replication-competent) adenoviruses as anticancer agents. Expert Opin Biol Ther 10: 353-368.
11. Yamamoto, M and Curiel, DT (2010). Current issues and future directions of oncolytic adenoviruses. Mol Ther 18: 243-250.
12. Choi, IK and Yun, CO (2013). Recent developments in oncolytic adenovirus-based immunotherapeutic agents for use against metastatic cancers. Cancer Gene Ther 20: 70-76.
13. Nakashima, H and Chiocca, EA (2014). Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus. J Virol 88: 345-353.
14. Burton, JB, Johnson, M, Sato, M, Koh, SB, Mulholland, DJ, Stout, D et al. (2008). Adenovirus-mediated gene expression imaging to directly detect sentinel lymph node metastasis of prostate cancer. Nat Med 14: 882-888.
15. de Vrij, J, Willemsen, RA, Lindholm, L, Hoeben, RC, Bangma, CH, Barber, C et al. ; GIANT Consortium. (2010). Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther 21: 795-805.
16. Schenk, E, Essand, M, Bangma, CH, Barber, C, Behr, JP, Briggs, S et al. ; GIANT FP6 Consortium. (2010). Clinical adenoviral gene therapy for prostate cancer. Hum Gene Ther 21: 807-813.
17. Hu, Z, Gupta, J, Zhang, Z, Gerseny, H, Berg, A, Chen, YJ et al. (2012). Systemic delivery of oncolytic adenoviruses targeting transforming growth factor-â inhibits established bone metastasis in a prostate cancer mouse model. Hum Gene Ther 23: 871-882.
18. Juárez, P and Guise, TA (2011). TGF-â in cancer and bone: implications for treatment of bone metastases. Bone 48: 23-29.
19. Jones, E, Pu, H and Kyprianou, N (2009). Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets 13: 227-234.
20. Lieber, A, He, CY, Meuse, L, Schowalter, D, Kirillova, I, Winther, B et al. (1997). The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71: 8798-8807.
21. Xu, Z, Tian, J, Smith, JS and Byrnes, AP (2008). Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complement. J Virol 82: 11705-11713.
22. Khare, R, Chen, CY, Weaver, EA and Barry, MA (2011). Advances and future challenges in adenoviral vector pharmacology and targeting. Curr Gene Ther 11: 241-258.
23. Doronin, K, Flatt, JW, Di Paolo, NC, Khare, R, Kalyuzhniy, O, Acchione, M et al. (2012). Coagulation factor X activates innate immunity to human species C adenovirus. Science 338: 795-798.
24. Green, NK, Herbert, CW, Hale, SJ, Hale, AB, Mautner, V, Harkins, R et al. (2004). Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 11: 1256-1263.
25. Hu, Z, Gerseny, H, Zhang, Z, Chen, YJ, Berg, A, Stock, S et al. (2011). Oncolytic adenovirus expressing soluble TGFbeta receptor II-Fc-mediated inhibition of established bone metastases: a safe and effective systemic therapeutic approach for breast cancer. Mol Ther 9: 1609-1618.
26. Ahi, YS, Bangari, DS and Mittal, SK (2011). Adenoviral vector immunity: its implications and circumvention strategies. Curr Gene Ther 11: 307-320.
27. Manickan, E, Smith, JS, Tian, J, Eggerman, TL, Lozier, JN, Muller, J et al. (2006). Rapid Kupffer cell death after intravenous injection of adenovirus vectors. Mol Ther 13: 108-117.
28. Engler, H, Machemer, T, Philopena, J, Wen, SF, Quijano, E, Ramachandra, M et al. (2004). Acute hepatotoxicity of oncolytic adenoviruses in mouse models is associated with expression of wild-type E1a and induction of TNF-alpha. Virology 328: 52-61.
29. Parker, AL, Waddington, SN, Nicol, CG, Shayakhmetov, DM, Buckley, SM, Denby, L et al. (2006). Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood 108: 2554-2561.
30. Roberts, DM, Nanda, A, Havenga, MJ, Abbink, P, Lynch, DM, Ewald, BA et al. (2006). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243.
31. Kalyuzhniy, O, Di Paolo, NC, Silvestry, M, Hofherr, SE, Barry, MA, Stewart, PL et al. (2008). Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. Proc Natl Acad Sci USA 105: 5483-5488.
32. Alba, R, Bradshaw, AC, Parker, AL, Bhella, D, Waddington, SN, Nicklin, SA et al. (2009). Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer. Blood 114: 965-971.
33. Zhang, Z, Krimmel, J, Zhang, Z, Hu, Z and Seth, P (2011). Systemic delivery of a novel liver-detargeted oncolytic adenovirus causes reduced liver toxicity but maintains the antitumor response in a breast cancer bone metastasis model. Hum Gene Ther 22: 1137-1142.
34. Seth, P, Wang, ZG, Pister, A, Zafar, MB, Kim, S, Guise, T et al. (2006). Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. Hum Gene Ther 17: 1152-1160.
35. Yu, D, Jin, C, Ramachandran, M, Xu, J, Nilsson, B, Korsgren, O et al. (2013). Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures. PLoS One 8: e54952.
36. Tao, N, Gao, GP, Parr, M, Johnston, J, Baradet, T, Wilson, JM et al. (2001). Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 3: 28-35.
37. Ogawara, K, Rots, MG, Kok, RJ, Moorlag, HE, Van Loenen, AM, Meijer, DK et al. (2004). A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum Gene Ther 15: 433-443.
38. Schiedner, G, Bloch, W, Hertel, S, Johnston, M, Molojavyi, A, Dries, V et al. (2003). A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 14: 1631-1641.
39. Coughlan, L, Bradshaw, AC, Parker, AL, Robinson, H, White, K, Custers, J et al. (2012). Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery. Mol Ther 20: 2268-2281.
40. Reid, T, Warren, R and Kirn, D (2002). Intravascular adenoviral agents in cancer patients: lessons from clinical trials. Cancer Gene Ther 9: 979-986.
41. Nemunaitis, J, Cunningham, C, Buchanan, A, Blackburn, A, Edelman, G, Maples, P et al. (2001). Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8: 746-759.
42. Small, EJ, Carducci, MA, Burke, JM, Rodriguez, R, Fong, L, van Ummersen, L et al. (2006). A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther 14: 107-117.
43. Hamid, O, Varterasian, ML, Wadler, S, Hecht, JR, Benson, A 3rd, Galanis, E et al. (2003). Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 21: 1498-1504.
44. Xu, Z, Qiu, Q, Tian, J, Smith, JS, Conenello, GM, Morita, T et al. (2013). Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement. Nat Med 19: 452-457.
45. Loberg, RD, Day, LL, Dunn, R, Kalikin, LM and Pienta, KJ (2006). Inhibition of decayaccelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8: 69-78.
46. Katayose, D, Gudas, J, Nguyen, H, Srivastava, S, Cowan, KH and Seth, P (1995). Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res 1: 889-897.
47. Zhang, Z, Hu, Z, Gupta, J, Krimmel, JD, Gerseny, HM, Berg, AF et al. (2012). Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther 19: 630-636.
48. Hu, Z, Zhang, Z, Guise, T and Seth, P (2010). Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-â receptor II-Fc fusion protein can inhibit breast cancer bone metastasis in a mouse model. Hum Gene Ther 21: 1623-1629.
49. Wang, YX, Carlo, FD, Mancini, DC, McNulty, I, Tieman, B, Bresnahan, J et al. (2001). A high-throughput X-ray microtomography system at the Advanced Photon Source. Rev Sci Instr 72: 2062-2068.